Nucleic acids for molecular diagnosis refer to the use of DNA or RNA molecules to detect, identify, or quantify specific genetic sequences associated with diseases, pathogens, or other biological conditions. Molecular diagnosis using nucleic acids is a cornerstone of modern diagnostics, offering highly sensitive and specific methods for identifying genetic mutations, infectious agents, and other molecular markers.
The global Nucleic Acids for Molecular Diagnosis market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
The 鈥淣ucleic Acids for Molecular Diagnosis Industry Forecast鈥� looks at past sales and reviews total world Nucleic Acids for Molecular Diagnosis sales in 2022, providing a comprehensive analysis by region and market sector of projected Nucleic Acids for Molecular Diagnosis sales for 2023 through 2029. With Nucleic Acids for Molecular Diagnosis sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Nucleic Acids for Molecular Diagnosis industry.
This Insight Report provides a comprehensive analysis of the global Nucleic Acids for Molecular Diagnosis landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Nucleic Acids for Molecular Diagnosis portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Nucleic Acids for Molecular Diagnosis market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Nucleic Acids for Molecular Diagnosis and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Nucleic Acids for Molecular Diagnosis.
United States market for Nucleic Acids for Molecular Diagnosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Nucleic Acids for Molecular Diagnosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Nucleic Acids for Molecular Diagnosis is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Nucleic Acids for Molecular Diagnosis players cover Danaher Corporation, Merck KGaA, Eurofins Scientific SE, Thermo Fisher Scientific Inc., Agilent Technologies, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Nucleic Acids for Molecular Diagnosis market by product type, application, key players and key regions and countries.
Segmentation by Type:
DNA Series
RNA Series
Segmentation by Application:
Infectious Diseases
Early Cancer Screening
Blood Screening
Genetic Diseases
Genome Sequencing
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
Segmentation by Type:
DNA Series
RNA Series
Segmentation by Application:
Infectious Diseases
Early Cancer Screening
Blood Screening
Genetic Diseases
Genome Sequencing
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Danaher Corporation
Merck KGaA
Eurofins Scientific SE
Thermo Fisher Scientific Inc.
Agilent Technologies, Inc.
Kaneka Eurogentec S.A.
Aji Bio-Pharma
L.G.C Biosearch Technologies
Integrated DNA Technologies
Bio-synthesis Inc.
metabion
QIAGEN
Hongene
Synthgene
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nucleic Acids for Molecular Diagnosis Market Size 2019-2030
2.1.2 Nucleic Acids for Molecular Diagnosis Market Size CAGR by Region (2019 VS 2023 VS 2030)
2.1.3 World Current & Future Analysis for Nucleic Acids for Molecular Diagnosis by Country/Region, 2019, 2023 & 2030
2.2 Nucleic Acids for Molecular Diagnosis Segment by Type
2.2.1 DNA Series
2.2.2 RNA Series
2.3 Nucleic Acids for Molecular Diagnosis Market Size by Type
2.3.1 Nucleic Acids for Molecular Diagnosis Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Nucleic Acids for Molecular Diagnosis Market Size Market Share by Type (2019-2024)
2.4 Nucleic Acids for Molecular Diagnosis Segment by Application
2.4.1 Infectious Diseases
2.4.2 Early Cancer Screening
2.4.3 Blood Screening
2.4.4 Genetic Diseases
2.4.5 Genome Sequencing
2.4.6 Other
2.5 Nucleic Acids for Molecular Diagnosis Market Size by Application
2.5.1 Nucleic Acids for Molecular Diagnosis Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Nucleic Acids for Molecular Diagnosis Market Size Market Share by Application (2019-2024)
3 Nucleic Acids for Molecular Diagnosis Market Size by Player
3.1 Nucleic Acids for Molecular Diagnosis Market Size Market Share by Player
3.1.1 Global Nucleic Acids for Molecular Diagnosis Revenue by Player (2019-2024)
3.1.2 Global Nucleic Acids for Molecular Diagnosis Revenue Market Share by Player (2019-2024)
3.2 Global Nucleic Acids for Molecular Diagnosis Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Nucleic Acids for Molecular Diagnosis by Region
4.1 Nucleic Acids for Molecular Diagnosis Market Size by Region (2019-2024)
4.2 Global Nucleic Acids for Molecular Diagnosis Annual Revenue by Country/Region (2019-2024)
4.3 Americas Nucleic Acids for Molecular Diagnosis Market Size Growth (2019-2024)
4.4 APAC Nucleic Acids for Molecular Diagnosis Market Size Growth (2019-2024)
4.5 Europe Nucleic Acids for Molecular Diagnosis Market Size Growth (2019-2024)
4.6 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size Growth (2019-2024)
5 Americas
5.1 Americas Nucleic Acids for Molecular Diagnosis Market Size by Country (2019-2024)
5.2 Americas Nucleic Acids for Molecular Diagnosis Market Size by Type (2019-2024)
5.3 Americas Nucleic Acids for Molecular Diagnosis Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleic Acids for Molecular Diagnosis Market Size by Region (2019-2024)
6.2 APAC Nucleic Acids for Molecular Diagnosis Market Size by Type (2019-2024)
6.3 APAC Nucleic Acids for Molecular Diagnosis Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Nucleic Acids for Molecular Diagnosis Market Size by Country (2019-2024)
7.2 Europe Nucleic Acids for Molecular Diagnosis Market Size by Type (2019-2024)
7.3 Europe Nucleic Acids for Molecular Diagnosis Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nucleic Acids for Molecular Diagnosis by Region (2019-2024)
8.2 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Type (2019-2024)
8.3 Middle East & Africa Nucleic Acids for Molecular Diagnosis Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Nucleic Acids for Molecular Diagnosis Market Forecast
10.1 Global Nucleic Acids for Molecular Diagnosis Forecast by Region (2025-2030)
10.1.1 Global Nucleic Acids for Molecular Diagnosis Forecast by Region (2025-2030)
10.1.2 Americas Nucleic Acids for Molecular Diagnosis Forecast
10.1.3 APAC Nucleic Acids for Molecular Diagnosis Forecast
10.1.4 Europe Nucleic Acids for Molecular Diagnosis Forecast
10.1.5 Middle East & Africa Nucleic Acids for Molecular Diagnosis Forecast
10.2 Americas Nucleic Acids for Molecular Diagnosis Forecast by Country (2025-2030)
10.2.1 United States Market Nucleic Acids for Molecular Diagnosis Forecast
10.2.2 Canada Market Nucleic Acids for Molecular Diagnosis Forecast
10.2.3 Mexico Market Nucleic Acids for Molecular Diagnosis Forecast
10.2.4 Brazil Market Nucleic Acids for Molecular Diagnosis Forecast
10.3 APAC Nucleic Acids for Molecular Diagnosis Forecast by Region (2025-2030)
10.3.1 China Nucleic Acids for Molecular Diagnosis Market Forecast
10.3.2 Japan Market Nucleic Acids for Molecular Diagnosis Forecast
10.3.3 Korea Market Nucleic Acids for Molecular Diagnosis Forecast
10.3.4 Southeast Asia Market Nucleic Acids for Molecular Diagnosis Forecast
10.3.5 India Market Nucleic Acids for Molecular Diagnosis Forecast
10.3.6 Australia Market Nucleic Acids for Molecular Diagnosis Forecast
10.4 Europe Nucleic Acids for Molecular Diagnosis Forecast by Country (2025-2030)
10.4.1 Germany Market Nucleic Acids for Molecular Diagnosis Forecast
10.4.2 France Market Nucleic Acids for Molecular Diagnosis Forecast
10.4.3 UK Market Nucleic Acids for Molecular Diagnosis Forecast
10.4.4 Italy Market Nucleic Acids for Molecular Diagnosis Forecast
10.4.5 Russia Market Nucleic Acids for Molecular Diagnosis Forecast
10.5 Middle East & Africa Nucleic Acids for Molecular Diagnosis Forecast by Region (2025-2030)
10.5.1 Egypt Market Nucleic Acids for Molecular Diagnosis Forecast
10.5.2 South Africa Market Nucleic Acids for Molecular Diagnosis Forecast
10.5.3 Israel Market Nucleic Acids for Molecular Diagnosis Forecast
10.5.4 Turkey Market Nucleic Acids for Molecular Diagnosis Forecast
10.6 Global Nucleic Acids for Molecular Diagnosis Forecast by Type (2025-2030)
10.7 Global Nucleic Acids for Molecular Diagnosis Forecast by Application (2025-2030)
10.7.1 GCC Countries Market Nucleic Acids for Molecular Diagnosis Forecast
11 Key Players Analysis
11.1 Danaher Corporation
11.1.1 Danaher Corporation Company Information
11.1.2 Danaher Corporation Nucleic Acids for Molecular Diagnosis Product Offered
11.1.3 Danaher Corporation Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Danaher Corporation Main Business Overview
11.1.5 Danaher Corporation Latest Developments
11.2 Merck KGaA
11.2.1 Merck KGaA Company Information
11.2.2 Merck KGaA Nucleic Acids for Molecular Diagnosis Product Offered
11.2.3 Merck KGaA Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Merck KGaA Main Business Overview
11.2.5 Merck KGaA Latest Developments
11.3 Eurofins Scientific SE
11.3.1 Eurofins Scientific SE Company Information
11.3.2 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Product Offered
11.3.3 Eurofins Scientific SE Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Eurofins Scientific SE Main Business Overview
11.3.5 Eurofins Scientific SE Latest Developments
11.4 Thermo Fisher Scientific Inc.
11.4.1 Thermo Fisher Scientific Inc. Company Information
11.4.2 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Product Offered
11.4.3 Thermo Fisher Scientific Inc. Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Thermo Fisher Scientific Inc. Main Business Overview
11.4.5 Thermo Fisher Scientific Inc. Latest Developments
11.5 Agilent Technologies, Inc.
11.5.1 Agilent Technologies, Inc. Company Information
11.5.2 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Product Offered
11.5.3 Agilent Technologies, Inc. Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Agilent Technologies, Inc. Main Business Overview
11.5.5 Agilent Technologies, Inc. Latest Developments
11.6 Kaneka Eurogentec S.A.
11.6.1 Kaneka Eurogentec S.A. Company Information
11.6.2 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Product Offered
11.6.3 Kaneka Eurogentec S.A. Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Kaneka Eurogentec S.A. Main Business Overview
11.6.5 Kaneka Eurogentec S.A. Latest Developments
11.7 Aji Bio-Pharma
11.7.1 Aji Bio-Pharma Company Information
11.7.2 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Product Offered
11.7.3 Aji Bio-Pharma Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Aji Bio-Pharma Main Business Overview
11.7.5 Aji Bio-Pharma Latest Developments
11.8 L.G.C Biosearch Technologies
11.8.1 L.G.C Biosearch Technologies Company Information
11.8.2 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Product Offered
11.8.3 L.G.C Biosearch Technologies Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 L.G.C Biosearch Technologies Main Business Overview
11.8.5 L.G.C Biosearch Technologies Latest Developments
11.9 Integrated DNA Technologies
11.9.1 Integrated DNA Technologies Company Information
11.9.2 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Product Offered
11.9.3 Integrated DNA Technologies Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Integrated DNA Technologies Main Business Overview
11.9.5 Integrated DNA Technologies Latest Developments
11.10 Bio-synthesis Inc.
11.10.1 Bio-synthesis Inc. Company Information
11.10.2 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Product Offered
11.10.3 Bio-synthesis Inc. Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Bio-synthesis Inc. Main Business Overview
11.10.5 Bio-synthesis Inc. Latest Developments
11.11 metabion
11.11.1 metabion Company Information
11.11.2 metabion Nucleic Acids for Molecular Diagnosis Product Offered
11.11.3 metabion Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 metabion Main Business Overview
11.11.5 metabion Latest Developments
11.12 QIAGEN
11.12.1 QIAGEN Company Information
11.12.2 QIAGEN Nucleic Acids for Molecular Diagnosis Product Offered
11.12.3 QIAGEN Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 QIAGEN Main Business Overview
11.12.5 QIAGEN Latest Developments
11.13 Hongene
11.13.1 Hongene Company Information
11.13.2 Hongene Nucleic Acids for Molecular Diagnosis Product Offered
11.13.3 Hongene Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Hongene Main Business Overview
11.13.5 Hongene Latest Developments
11.14 Synthgene
11.14.1 Synthgene Company Information
11.14.2 Synthgene Nucleic Acids for Molecular Diagnosis Product Offered
11.14.3 Synthgene Nucleic Acids for Molecular Diagnosis Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Synthgene Main Business Overview
11.14.5 Synthgene Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
